FHIR Implementation Guide for HCX
0.7.0 - CI Build
FHIR Implementation Guide for HCX
0.7.0 - CI Build
FHIR Implementation Guide for HCX - Local Development build (v0.7.0). See the Directory of published versions
{
"resourceType" : "ValueSet",
"id" : "informational-messages-codes",
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>This value set contains 136 concepts</p><table class=\"codes\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>System</b></td><td><b>Display</b></td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MG045A\"> </a> MG045A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Dialysis payable separately as an add on package</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MG072A\"> </a> MG072A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Package cost of one session</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MG075A\"> </a> MG075A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Rs. 5000 is the upper limit.\nCan be booked at a lower rate also.\nIn fact the SHA should examine this package and confirm wheter the package has been booked at the usual market rate.\nCan be booked for a pt. already admitted under any medical package.</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO014F\"> </a> MO014F</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant and adjuvant rectal cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO062A1\"> </a> MO062A1</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>ACUTE LYMPHOBLASTIC LEUKEMIA</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MR001A\"> </a> MR001A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>The Procedure will cover ALL, Hodgkin's Lymphoma, Wilm's Tumour, NHL, Retinoblastoma & certain Bone Tumours`</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SB030A\"> </a> SB030A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Can be used for ORIF, wherever indicated.\nCan not be used as an Add - on package</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SB032A\"> </a> SB032A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Surgical Management for Type III & IV Rockwood to be decided by the surgeon on case to case basis\nType V & VI to be taken up for Surgery straight away\nIn case Type I or II is booked a Pop Up to be shown "For Rockwood Type I & II - AC Joint injury, experts recommend Medical Management, are you sure you want to do Surgical Correction in this case ?" \nFor Hospitals booking Surgical Correction in Type I & Type II cases, Medical Audit will be conducted.</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SB032C\"> </a> SB032C</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Surgical Management for Type III & IV Rockwood to be decided by the surgeon on case to case basis\nType V & VI to be taken up for Surgery straight away</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SB070A\"> </a> SB070A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>LA for - K Wire & Screw\nGA for - Nail & Plate</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SC076A\"> </a> SC076A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>If the Hospital choses Pediatric Port in a pt. aged more than 14 years. Then it should be audited</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SE012A\"> </a> SE012A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>The package is inclusive of Eye Bank processing fee</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SE012B\"> </a> SE012B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>This is a special follow up package, as in Corneal graft surgery, a follow up at 1 week is required.\nAt this time, the surgeon has to examine and then prescribe medicine for next one month.\nThe medicine for 1 month has to be given at the time of booking this package.\nA signed reciept from the pt. is an essential document</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SE018A\"> </a> SE018A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>To be done only after a prior scleral buckling surgery history</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SE022A\"> </a> SE022A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Can be booked only after 1 year of cataract surgery</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SE025A\"> </a> SE025A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Can be booked as a complication of cataract surgery atleast 15 days after discharge</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SE029A\"> </a> SE029A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>The procedure is done only once per eye and not repeated</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SE029B\"> </a> SE029B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>1. Claim to be raised after all 3 sittings have been done per eye.\n2. The interval between subsequent sittings is atleast 1 week.</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SE033A\"> </a> SE033A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Pre-auth to be raised only in cases which have a prior history of Vitreoretinal surgery done atleast 3 months ago</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SG097A\"> </a> SG097A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Can be booked only after 15 days of Ileostomy and then every 2 months thereafter till the closure of stoma.\nThe Hospital has to upload a signed statement from pt. that s/he has received the cosnumables: Ileostomy - bags, adhesive, clips etc for 2 months</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SG097B\"> </a> SG097B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Can be booked only after 15 days of Colostomy and then every 2 months thereafter till the closure of stoma.\nThe Hospital has to upload a signed statement from pt. that s/he has received the cosnumables: colostomy - bags, adhesive, clips etc for 2 months</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SU052A\"> </a> SU052A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Payment to be made after completion of one month.</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SU060A\"> </a> SU060A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Claim to be raised after 6th Cycle</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SU060B\"> </a> SU060B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Claim for Rs. 15,000 can be raised after 6th Cycle.\nRemainaing Rs. 15,000 can be claimed after 12th Cycle</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SU071C\"> </a> SU071C</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>No payment to be done to the Hospital for this stage\nThe package can be booked only if the first stage package has been booked prior to this</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SU071D\"> </a> SU071D</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>The package can be booked only if the first stage and / or intermediate stage package has been booked prior to this</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SV032A\"> </a> SV032A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Associated with CABG\nNeed to submit Barcode/ ID number of IABP. Intra-operative use of IABP as a part of operative strategy, not included\nIncidence - 5% to 7%\nScrutiny of Hospitals where incidence is more than twice of prescribed limit</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO001A\"> </a> MO001A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Adjuvant therapy in breast cancer\nMetastatic breast cancer\n(should not have received the same regimen or AC earlier)</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO001B\"> </a> MO001B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Adjuvant therapy after 4 cycles of AC or EC</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO001C\"> </a> MO001C</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metstatic breast cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO001D\"> </a> MO001D</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Adjuvant therapy in breast cancer with cardiac dysfunction or not suitable for anthracycline based therapy\nMetstatic breast cancer\n(should not have received the same regimen earlier)</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO001E\"> </a> MO001E</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Adjuvant therapy in breast cancer with cardiac dysfunction or not suitable for anthracycline based therapy and high nodal burden\nMetastatic breast cancer\n(should not have received the same regimen earlier)</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO001F\"> </a> MO001F</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Adjuvant therapy in breast cancer with Her-2 neu positive patients</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO001G\"> </a> MO001G</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Adjuvant or neoadjuvant therapy in ER / PR psotive breast cancer\nER / PR positive metastatic breast cancer\n(if not receive earlier)</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO001H\"> </a> MO001H</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Adjuvant or neoadjuvant therapy in ER / PR psotive breast cancer\nER / PR positive metastatic breast cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO001I\"> </a> MO001I</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Adjuvant or neoadjuvant therapy breast cancer\nmetastatic breast cancer\n(if not received earlier)</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO001L\"> </a> MO001L</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Adjuvant therapy in breast cancer\nMetstatic breast cancer\n(should not have received the same regimen or EC earlier)</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO001M\"> </a> MO001M</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic breast cancer ER / PR positive</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO001N\"> </a> MO001N</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Adjuvant or neoadjuvant therapy breast cancer\nmetastatic breast cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO001O\"> </a> MO001O</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic breast cancer ER / PR positive</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO002A\"> </a> MO002A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic bone malignancy and multiple myeloma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO003A\"> </a> MO003A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic ovarian adenocarcinoma second line</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO003B\"> </a> MO003B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant, adjuvant and metastatic ovarian adenocarcinoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO004A\"> </a> MO004A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Testicular Seminoma, Adjuvant</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO004B\"> </a> MO004B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Germ cell tumour of any site for Neoadjuvant, adjuvant or metastatic first line</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO004D\"> </a> MO004D</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Germ cell tumour second line therapy</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO005A\"> </a> MO005A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>First line therapy for high - risk Gestational Trophoblastic Neoplasia\nSecond line</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO005C\"> </a> MO005C</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>First line therapy for low risk Gestational Trophoblastic Neoplasia</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO006A\"> </a> MO006A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant and metastatic Cervical Cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO006B\"> </a> MO006B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Stage II and Stage III cervical cancer definitive therapy along with Radiation therapy</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO007A\"> </a> MO007A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant, Adjuvant and Metastatic Endometrial Cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO007B\"> </a> MO007B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic Endometrial Cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO008A\"> </a> MO008A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>NACT, mets</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO008B\"> </a> MO008B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Stage II and Stage III cervical cancer definitive therapy</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO009A\"> </a> MO009A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Ewing Sarcoma second line chemotherapy</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO010A\"> </a> MO010A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Osteogenic carcinoma Neoadjuvant and adjuvant therapy</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO010B\"> </a> MO010B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Relapsed Osteogenic Sarcoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO010C\"> </a> MO010C</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Osteogenic carcinoma Neoadjuvant therapy</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO010D\"> </a> MO010D</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Osteogenic carcinoma adjuvant therapy</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO011A\"> </a> MO011A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>NACT, Adjuvant, mets (if cardiac dysfunction)</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO011B\"> </a> MO011B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Soft tissue sarcoma neoadjuvant, adjuvant and metastatic</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO012A\"> </a> MO012A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic Melanoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO013A\"> </a> MO013A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Stage II and III anal Cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO013C\"> </a> MO013C</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic Anal Cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO014A\"> </a> MO014A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Adjuvant and Metastatic Colorectal Cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO014B\"> </a> MO014B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic Colorectal Cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO014H\"> </a> MO014H</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant and adjuvant Colorectal Cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO015A\"> </a> MO015A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant and adjuvant esophageal cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO015B\"> </a> MO015B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Upper esophageal neoadjuvant and with RT as adjuvant</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO015D\"> </a> MO015D</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>With RT in definitive non-metastatic</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO015E\"> </a> MO015E</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic without RT</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO016B\"> </a> MO016B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic second line esophageal and stomach cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO016C\"> </a> MO016C</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Till RT ends\nLower esophageal and stomach Cancer with RT as adjuvant</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO016D\"> </a> MO016D</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Till completion of RT\nLower esophageal and stomach Cancer with RT as adjuvant</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO016E\"> </a> MO016E</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Adjuvant and Metastatic Stomach, Lower esophageal (adenocarcinoma) cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO016F\"> </a> MO016F</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant, adjuvant and metastatic stomach and lower esophageal (adenocarcinoma) cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO016J\"> </a> MO016J</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metatstaic lower esophageal and stomach Cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO016K\"> </a> MO016K</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Adjuvant for stomach and lower esophageal (adenocarcinoma) cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO016L\"> </a> MO016L</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant, adjuvant, along with Radiation (concurrent), metastatic esophageal cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO017A\"> </a> MO017A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Liver confined hepatocellular carcinoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO017B\"> </a> MO017B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Meatastatic hepatocellular carcinoma (except child Pugh c)\nLiver confined but not suitable for liver directed therapy</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO018B\"> </a> MO018B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic pancreatic cancer - first line</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO018C\"> </a> MO018C</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant and adjuvant locally advanced pancreatic cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO018E\"> </a> MO018E</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Till RT ends\nNeoadjuvant and adjuvant locally advanced pancreatic cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO018F\"> </a> MO018F</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Pancreatic cancer - adjuvant</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO019A\"> </a> MO019A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Adjuvant and metastatic gall bladder and cholnagicarcinoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO019B\"> </a> MO019B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant, adjuvant and metastatic pancreatic cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO019C\"> </a> MO019C</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic gall bladder and cholngiocarcinoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO019D\"> </a> MO019D</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Till RT ends\nDefinitive and Adjuvant therapy in gall bladder cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO019E\"> </a> MO019E</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metatstatic Gall Bladder Cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO020A\"> </a> MO020A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant, adjuvant and metastatic GIST</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO020B\"> </a> MO020B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic GIST</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO021A\"> </a> MO021A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Adjuvant therapy</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO022A\"> </a> MO022A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic mesothelioma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO022B\"> </a> MO022B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant,adjuvant and metastatic mesothelioma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO023A\"> </a> MO023A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant Chemotherapy and metastatic thymic carcinoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO024A\"> </a> MO024A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant and metastatic head and neck squamou cell cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO024B\"> </a> MO024B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Definitive therapy</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO024C\"> </a> MO024C</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic squamous cell head and neck cancer, nasopharyngeal cancer, salivary gland cancers</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO024D\"> </a> MO024D</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant, Metastatic squamou cell head and neck cancer, nasopharyngeal cancer, salivary gland cancers</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO024E\"> </a> MO024E</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic squamou cell head and neck cancer, salivary gland cancers</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO024F\"> </a> MO024F</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic Head and neck squamous cell carcinoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO024G\"> </a> MO024G</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant, adjuvant and metastatic esthesioneuroblastoma and Neuroendocrine carcinoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO024L\"> </a> MO024L</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic squamous cell head and neck cancer, salivary gland cancers, nasopharyngeal carcinoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO024M\"> </a> MO024M</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic squamous cell head and neck cancer, salivary gland cancers</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO025A\"> </a> MO025A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic renal cell carcinoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO026A\"> </a> MO026A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant, Metastatic urothelial cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO026B\"> </a> MO026B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant, Adjuvant, Metastatic urothelial cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO026F\"> </a> MO026F</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic urothelial cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO027A\"> </a> MO027A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant, Adjuvant, Metastatic penile cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO027C\"> </a> MO027C</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic Penile Cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO028A\"> </a> MO028A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic prostate cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO033A\"> </a> MO033A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Multiagent chemotherapy variable in each protocol</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO047C\"> </a> MO047C</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Optional Vincristine and Prednsiolone\nIntrathecal Methotrexate</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO048C\"> </a> MO048C</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Optional Vincristine and Prednsiolone, intrathecal Methotrexate</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO054A\"> </a> MO054A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Histiocytosis Protocol - Induction</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO054B\"> </a> MO054B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Histiocytosis Protocol - Maintenance</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO055A\"> </a> MO055A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Low Grade Glioma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO056A\"> </a> MO056A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Medulloblastoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO057A\"> </a> MO057A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neuroblastoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO058A\"> </a> MO058A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Retinoblastoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO059A\"> </a> MO059A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Rhabdomyosarcoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO060A\"> </a> MO060A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Relapsed Rhabdomyosarcoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO062A\"> </a> MO062A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Phase II, CNS Therapy Reinduction</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO066A\"> </a> MO066A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Relapsed Hodgkins Lymphoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO066B\"> </a> MO066B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Hodgkins Lymphoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO068A\"> </a> MO068A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Non - Hodgkins Lymphoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO071A\"> </a> MO071A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metstatic non small cell lung cancer - second line</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO071E\"> </a> MO071E</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic non small cell lung (adenocarcinoma) cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO071F\"> </a> MO071F</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic small cell lung cancer - second line</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO071G\"> </a> MO071G</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic Non Small Cell Lung Cancer - in patients unfit for combination therapy</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO071H\"> </a> MO071H</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant, concurrent with radiation and metastaic small cell lung cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO071K\"> </a> MO071K</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant and Metastatic Non Small Cell Lung cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO071O\"> </a> MO071O</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Concurrent chemoradiation in Non Small Cell lung cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO071Q\"> </a> MO071Q</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant, Adjuvant and Metastatic Non Small Cell Lung cancer (adnocarcinoma and adenosquamous carcinoma)</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO071R\"> </a> MO071R</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic non small cell lung cancer (adenocarcinoma) as maintenance after\nCarboplatin + Pemetrexed and\nCisplatin + Pemetrexed 4 -6 cycles</td></tr></table></div>"
},
"url" : "https://ig.hcxprotocol.io/v0.7/ValueSet-informational-messages-codes.html",
"version" : "0.7.0",
"name" : "InformationalMessagesCodes",
"status" : "active",
"date" : "2022-06-01",
"publisher" : "HCX Open Community",
"contact" : [
{
"name" : "HCX Open Community",
"telecom" : [
{
"system" : "url",
"value" : "http://hcxprotocol.io/"
}
]
}
],
"description" : "This is the value set that includes the informational messages codes",
"expansion" : {
"timestamp" : "2022-06-01T08:15:30+05:30",
"contains" : [
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MG045A",
"display" : "Dialysis payable separately as an add on package"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MG072A",
"display" : "Package cost of one session"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MG075A",
"display" : "Rs. 5000 is the upper limit.\nCan be booked at a lower rate also.\nIn fact the SHA should examine this package and confirm wheter the package has been booked at the usual market rate.\nCan be booked for a pt. already admitted under any medical package."
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO014F",
"display" : "Neoadjuvant and adjuvant rectal cancer"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO062A1",
"display" : "ACUTE LYMPHOBLASTIC LEUKEMIA"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MR001A",
"display" : "The Procedure will cover ALL, Hodgkin's Lymphoma, Wilm's Tumour, NHL, Retinoblastoma & certain Bone Tumours`"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "SB030A",
"display" : "Can be used for ORIF, wherever indicated.\nCan not be used as an Add - on package"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "SB032A",
"display" : "Surgical Management for Type III & IV Rockwood to be decided by the surgeon on case to case basis\nType V & VI to be taken up for Surgery straight away\nIn case Type I or II is booked a Pop Up to be shown \"For Rockwood Type I & II - AC Joint injury, experts recommend Medical Management, are you sure you want to do Surgical Correction in this case ?\" \nFor Hospitals booking Surgical Correction in Type I & Type II cases, Medical Audit will be conducted."
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "SB032C",
"display" : "Surgical Management for Type III & IV Rockwood to be decided by the surgeon on case to case basis\nType V & VI to be taken up for Surgery straight away"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "SB070A",
"display" : "LA for - K Wire & Screw\nGA for - Nail & Plate"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "SC076A",
"display" : "If the Hospital choses Pediatric Port in a pt. aged more than 14 years. Then it should be audited"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "SE012A",
"display" : "The package is inclusive of Eye Bank processing fee"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "SE012B",
"display" : "This is a special follow up package, as in Corneal graft surgery, a follow up at 1 week is required.\nAt this time, the surgeon has to examine and then prescribe medicine for next one month.\nThe medicine for 1 month has to be given at the time of booking this package.\nA signed reciept from the pt. is an essential document"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "SE018A",
"display" : "To be done only after a prior scleral buckling surgery history"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "SE022A",
"display" : "Can be booked only after 1 year of cataract surgery"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "SE025A",
"display" : "Can be booked as a complication of cataract surgery atleast 15 days after discharge"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "SE029A",
"display" : "The procedure is done only once per eye and not repeated"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "SE029B",
"display" : "1. Claim to be raised after all 3 sittings have been done per eye.\n2. The interval between subsequent sittings is atleast 1 week."
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "SE033A",
"display" : "Pre-auth to be raised only in cases which have a prior history of Vitreoretinal surgery done atleast 3 months ago"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "SG097A",
"display" : "Can be booked only after 15 days of Ileostomy and then every 2 months thereafter till the closure of stoma.\nThe Hospital has to upload a signed statement from pt. that s/he has received the cosnumables: Ileostomy - bags, adhesive, clips etc for 2 months"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "SG097B",
"display" : "Can be booked only after 15 days of Colostomy and then every 2 months thereafter till the closure of stoma.\nThe Hospital has to upload a signed statement from pt. that s/he has received the cosnumables: colostomy - bags, adhesive, clips etc for 2 months"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "SU052A",
"display" : "Payment to be made after completion of one month."
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "SU060A",
"display" : "Claim to be raised after 6th Cycle"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "SU060B",
"display" : "Claim for Rs. 15,000 can be raised after 6th Cycle.\nRemainaing Rs. 15,000 can be claimed after 12th Cycle"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "SU071C",
"display" : "No payment to be done to the Hospital for this stage\nThe package can be booked only if the first stage package has been booked prior to this"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "SU071D",
"display" : "The package can be booked only if the first stage and / or intermediate stage package has been booked prior to this"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "SV032A",
"display" : "Associated with CABG\nNeed to submit Barcode/ ID number of IABP. Intra-operative use of IABP as a part of operative strategy, not included\nIncidence - 5% to 7%\nScrutiny of Hospitals where incidence is more than twice of prescribed limit"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO001A",
"display" : "Adjuvant therapy in breast cancer\nMetastatic breast cancer\n(should not have received the same regimen or AC earlier)"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO001B",
"display" : "Adjuvant therapy after 4 cycles of AC or EC"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO001C",
"display" : "Metstatic breast cancer"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO001D",
"display" : "Adjuvant therapy in breast cancer with cardiac dysfunction or not suitable for anthracycline based therapy\nMetstatic breast cancer\n(should not have received the same regimen earlier)"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO001E",
"display" : "Adjuvant therapy in breast cancer with cardiac dysfunction or not suitable for anthracycline based therapy and high nodal burden\nMetastatic breast cancer\n(should not have received the same regimen earlier)"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO001F",
"display" : "Adjuvant therapy in breast cancer with Her-2 neu positive patients"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO001G",
"display" : "Adjuvant or neoadjuvant therapy in ER / PR psotive breast cancer\nER / PR positive metastatic breast cancer\n(if not receive earlier)"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO001H",
"display" : "Adjuvant or neoadjuvant therapy in ER / PR psotive breast cancer\nER / PR positive metastatic breast cancer"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO001I",
"display" : "Adjuvant or neoadjuvant therapy breast cancer\nmetastatic breast cancer\n(if not received earlier)"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO001L",
"display" : "Adjuvant therapy in breast cancer\nMetstatic breast cancer\n(should not have received the same regimen or EC earlier)"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO001M",
"display" : "Metastatic breast cancer ER / PR positive"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO001N",
"display" : "Adjuvant or neoadjuvant therapy breast cancer\nmetastatic breast cancer"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO001O",
"display" : "Metastatic breast cancer ER / PR positive"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO002A",
"display" : "Metastatic bone malignancy and multiple myeloma"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO003A",
"display" : "Metastatic ovarian adenocarcinoma second line"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO003B",
"display" : "Neoadjuvant, adjuvant and metastatic ovarian adenocarcinoma"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO004A",
"display" : "Testicular Seminoma, Adjuvant"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO004B",
"display" : "Germ cell tumour of any site for Neoadjuvant, adjuvant or metastatic first line"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO004D",
"display" : "Germ cell tumour second line therapy"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO005A",
"display" : "First line therapy for high - risk Gestational Trophoblastic Neoplasia\nSecond line"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO005C",
"display" : "First line therapy for low risk Gestational Trophoblastic Neoplasia"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO006A",
"display" : "Neoadjuvant and metastatic Cervical Cancer"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO006B",
"display" : "Stage II and Stage III cervical cancer definitive therapy along with Radiation therapy"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO007A",
"display" : "Neoadjuvant, Adjuvant and Metastatic Endometrial Cancer"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO007B",
"display" : "Metastatic Endometrial Cancer"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO008A",
"display" : "NACT, mets"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO008B",
"display" : "Stage II and Stage III cervical cancer definitive therapy"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO009A",
"display" : "Ewing Sarcoma second line chemotherapy"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO010A",
"display" : "Osteogenic carcinoma Neoadjuvant and adjuvant therapy"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO010B",
"display" : "Relapsed Osteogenic Sarcoma"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO010C",
"display" : "Osteogenic carcinoma Neoadjuvant therapy"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO010D",
"display" : "Osteogenic carcinoma adjuvant therapy"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO011A",
"display" : "NACT, Adjuvant, mets (if cardiac dysfunction)"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO011B",
"display" : "Soft tissue sarcoma neoadjuvant, adjuvant and metastatic"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO012A",
"display" : "Metastatic Melanoma"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO013A",
"display" : "Stage II and III anal Cancer"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO013C",
"display" : "Metastatic Anal Cancer"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO014A",
"display" : "Adjuvant and Metastatic Colorectal Cancer"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO014B",
"display" : "Metastatic Colorectal Cancer"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO014H",
"display" : "Neoadjuvant and adjuvant Colorectal Cancer"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO015A",
"display" : "Neoadjuvant and adjuvant esophageal cancer"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO015B",
"display" : "Upper esophageal neoadjuvant and with RT as adjuvant"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO015D",
"display" : "With RT in definitive non-metastatic"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO015E",
"display" : "Metastatic without RT"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO016B",
"display" : "Metastatic second line esophageal and stomach cancer"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO016C",
"display" : "Till RT ends\nLower esophageal and stomach Cancer with RT as adjuvant"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO016D",
"display" : "Till completion of RT\nLower esophageal and stomach Cancer with RT as adjuvant"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO016E",
"display" : "Adjuvant and Metastatic Stomach, Lower esophageal (adenocarcinoma) cancer"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO016F",
"display" : "Neoadjuvant, adjuvant and metastatic stomach and lower esophageal (adenocarcinoma) cancer"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO016J",
"display" : "Metatstaic lower esophageal and stomach Cancer"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO016K",
"display" : "Adjuvant for stomach and lower esophageal (adenocarcinoma) cancer"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO016L",
"display" : "Neoadjuvant, adjuvant, along with Radiation (concurrent), metastatic esophageal cancer"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO017A",
"display" : "Liver confined hepatocellular carcinoma"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO017B",
"display" : "Meatastatic hepatocellular carcinoma (except child Pugh c)\nLiver confined but not suitable for liver directed therapy"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO018B",
"display" : "Metastatic pancreatic cancer - first line"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO018C",
"display" : "Neoadjuvant and adjuvant locally advanced pancreatic cancer"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO018E",
"display" : "Till RT ends\nNeoadjuvant and adjuvant locally advanced pancreatic cancer"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO018F",
"display" : "Pancreatic cancer - adjuvant"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO019A",
"display" : "Adjuvant and metastatic gall bladder and cholnagicarcinoma"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO019B",
"display" : "Neoadjuvant, adjuvant and metastatic pancreatic cancer"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO019C",
"display" : "Metastatic gall bladder and cholngiocarcinoma"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO019D",
"display" : "Till RT ends\nDefinitive and Adjuvant therapy in gall bladder cancer"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO019E",
"display" : "Metatstatic Gall Bladder Cancer"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO020A",
"display" : "Neoadjuvant, adjuvant and metastatic GIST"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO020B",
"display" : "Metastatic GIST"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO021A",
"display" : "Adjuvant therapy"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO022A",
"display" : "Metastatic mesothelioma"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO022B",
"display" : "Neoadjuvant,adjuvant and metastatic mesothelioma"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO023A",
"display" : "Neoadjuvant Chemotherapy and metastatic thymic carcinoma"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO024A",
"display" : "Neoadjuvant and metastatic head and neck squamou cell cancer"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO024B",
"display" : "Definitive therapy"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO024C",
"display" : "Metastatic squamous cell head and neck cancer, nasopharyngeal cancer, salivary gland cancers"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO024D",
"display" : "Neoadjuvant, Metastatic squamou cell head and neck cancer, nasopharyngeal cancer, salivary gland cancers"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO024E",
"display" : "Metastatic squamou cell head and neck cancer, salivary gland cancers"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO024F",
"display" : "Metastatic Head and neck squamous cell carcinoma"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO024G",
"display" : "Neoadjuvant, adjuvant and metastatic esthesioneuroblastoma and Neuroendocrine carcinoma"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO024L",
"display" : "Metastatic squamous cell head and neck cancer, salivary gland cancers, nasopharyngeal carcinoma"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO024M",
"display" : "Metastatic squamous cell head and neck cancer, salivary gland cancers"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO025A",
"display" : "Metastatic renal cell carcinoma"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO026A",
"display" : "Neoadjuvant, Metastatic urothelial cancer"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO026B",
"display" : "Neoadjuvant, Adjuvant, Metastatic urothelial cancer"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO026F",
"display" : "Metastatic urothelial cancer"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO027A",
"display" : "Neoadjuvant, Adjuvant, Metastatic penile cancer"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO027C",
"display" : "Metastatic Penile Cancer"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO028A",
"display" : "Metastatic prostate cancer"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO033A",
"display" : "Multiagent chemotherapy variable in each protocol"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO047C",
"display" : "Optional Vincristine and Prednsiolone\nIntrathecal Methotrexate"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO048C",
"display" : "Optional Vincristine and Prednsiolone, intrathecal Methotrexate"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO054A",
"display" : "Histiocytosis Protocol - Induction"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO054B",
"display" : "Histiocytosis Protocol - Maintenance"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO055A",
"display" : "Low Grade Glioma"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO056A",
"display" : "Medulloblastoma"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO057A",
"display" : "Neuroblastoma"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO058A",
"display" : "Retinoblastoma"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO059A",
"display" : "Rhabdomyosarcoma"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO060A",
"display" : "Relapsed Rhabdomyosarcoma"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO062A",
"display" : "Phase II, CNS Therapy Reinduction"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO066A",
"display" : "Relapsed Hodgkins Lymphoma"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO066B",
"display" : "Hodgkins Lymphoma"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO068A",
"display" : "Non - Hodgkins Lymphoma"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO071A",
"display" : "Metstatic non small cell lung cancer - second line"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO071E",
"display" : "Metastatic non small cell lung (adenocarcinoma) cancer"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO071F",
"display" : "Metastatic small cell lung cancer - second line"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO071G",
"display" : "Metastatic Non Small Cell Lung Cancer - in patients unfit for combination therapy"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO071H",
"display" : "Neoadjuvant, concurrent with radiation and metastaic small cell lung cancer"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO071K",
"display" : "Neoadjuvant and Metastatic Non Small Cell Lung cancer"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO071O",
"display" : "Concurrent chemoradiation in Non Small Cell lung cancer"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO071Q",
"display" : "Neoadjuvant, Adjuvant and Metastatic Non Small Cell Lung cancer (adnocarcinoma and adenosquamous carcinoma)"
},
{
"system" : "http://hcxprotocol.io/codes/informational-messages-codes",
"code" : "MO071R",
"display" : "Metastatic non small cell lung cancer (adenocarcinoma) as maintenance after\nCarboplatin + Pemetrexed and\nCisplatin + Pemetrexed 4 -6 cycles"
}
]
}
}
IG © 2021+ HCX Open Community. Package hcxprotocol.io#0.7.0 based on FHIR 4.0.1. Generated 2022-11-04
Links: Table of Contents |
QA Report